@entity851 ( @entity851 ) is a major cause of perinatal mortality and morbidity. Postnatally, @entity12550 ( @entity12550 ) increases growth, increases circulating @entity9418 levels, and alters metabolism. Our aim was to determine if @entity12550 infusion to @entity851 fetal @entity742 would alter fetal growth and metabolism, and thus provide a potential intra-uterine treatment for the @entity851 fetus. We studied three groups of fetuses: control, @entity851 + vehicle and @entity851 +GH (n=5 all groups). @entity851 was induced by repeated embolisation of the placental vascular bed between 110 and 116 days of gestation (term=145 days). @entity12550 (3.5 mg/kg/day) or vehicle was infused in a pulsatile manner from 117 to 127 days of gestation. Embolisation reduced fetal growth rate by 25% (P<0.01) and reduced the weight of the fetal liver (20%), kidney (23%) and thymus (31%; all P<0.05). @entity12550 treatment further reduced the weight of the fetal kidneys (32%) and small intestine (35%; both P<0.04), but restored the relative @entity53741 (P<0.05). Embolisation decreased fetal plasma @entity9418 concentrations (48%, P<0.001) and increased @entity25121 ( @entity25121 ) concentrations (737%, P<0.002). @entity12550 treatment restored fetal plasma @entity9418 concentrations to control levels, while levels in @entity851 +vehicle fetuses stayed low (P<0.05 vs control). @entity25121 and @entity42525 concentrations were about sevenfold lower in amniotic fluid than in fetal plasma, but amniotic and plasma concentrations were closely correlated (r=0.75, P<0.0001 and r=0.55 P<0.0001 respectively). Embolisation transiently decreased fetal blood @entity26 content (40%, P<0.002), and increased blood @entity880 concentrations (213%, P<0.04). Both returned to pre-embolisation levels after embolisation stopped, but blood @entity413 concentrations declined steadily in @entity851 +vehicle fetuses. @entity12550 treatment maintained fetal blood @entity413 concentrations at control levels. Our study shows that @entity12550 infusion to the @entity851 fetal @entity742 restores fetal @entity9418 levels but does not improve fetal growth, and further reduces the fetal kidney and intestine weights. Thus, fetal @entity12550 therapy does not seem a promising treatment stratagem for the @entity851 fetus.

Chronic pulsatile infusion of XXXX to growth-restricted fetal @entity742 increases circulating fetal insulin-like growth factor-I levels but not fetal growth.

@entity851 :: ('MESH:D006130', 'Disease') :: ['Intra-uterine growth restriction', 'IUGR'] @entity742 :: ('9940', 'Species') :: ['sheep'] @entity12550 :: ('443329(Tax:9940)', 'Gene') :: ['growth hormone', 'GH'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity42525 :: ('443469(Tax:9940)', 'Gene') :: ['IGFBP-2'] @entity25121 :: ('443132(Tax:9940)', 'Gene') :: ['IGF binding protein 1', 'IGFBP-1'] @entity9418 :: ('443318(Tax:9940)', 'Gene') :: ['insulin-like growth factor (IGF)-I', 'IGF-I'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity53741 :: ('MESH:D020567', 'Disease') :: ['weight of the fetal thymus and liver'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity12550 :: (443329(Tax:9940),Gene) :: ['growth hormone']
